

Robin L Jones

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9179431/publications.pdf>

Version: 2024-02-01

399
papers

17,141
citations

18465

62
h-index

20343

116
g-index

413
all docs

413
docs citations

413
times ranked

17134
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	3.2	18
2	Risk factors for the development of local recurrence in extremity soft-tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 83-95.	1.1	6
3	Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type Fibromatosis. <i>Cancers</i> , 2022, 14, 709.	1.7	8
4	KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment. <i>Chemotherapy</i> , 2022, 67, 81-90.	0.8	10
5	Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells. <i>Clinical Cancer Research</i> , 2022, 28, 1701-1711.	3.2	17
6	Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas. <i>Biomedicines</i> , 2022, 10, 573.	1.4	8
7	Immunologic Gene Signature Analysis Correlates Myeloid Cells and M2 Macrophages with Time to Trabectedin Failure in Sarcoma Patients. <i>Cancers</i> , 2022, 14, 1290.	1.7	5
8	Efficacy of Eribulin in Soft Tissue Sarcomas. <i>Frontiers in Pharmacology</i> , 2022, 13, 869754.	1.6	9
9	Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma. <i>JAMA Oncology</i> , 2022, 8, 740.	3.4	12
10	A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 2306-2312.	3.2	17
11	Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature. <i>Cancers</i> , 2022, 14, 1832.	1.7	15
12	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	0.8	15
13	Machine learning for rhabdomyosarcoma histopathology. <i>Modern Pathology</i> , 2022, 35, 1193-1203.	2.9	9
14	Proteomic Profiling Identifies Co-Regulated Expression of Splicing Factors as a Characteristic Feature of Intravenous Leiomyomatosis. <i>Cancers</i> , 2022, 14, 2907.	1.7	2
15	Unraveling Desmoid-Type Fibromatosis-Specific Health-Related Quality of Life: Who Is at Risk for Poor Outcomes. <i>Cancers</i> , 2022, 14, 2979.	1.7	5
16	Management of Vascular Sarcoma. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 485-510.	0.6	2
17	Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study. <i>European Journal of Cancer</i> , 2022, 171, 183-192.	1.3	4
18	Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Annals of Surgical Oncology</i> , 2022, 29, 7335-7348.	0.7	13

#	ARTICLE	IF	CITATIONS
19	Immunotherapy of sarcomas with modified T cells. <i>Current Opinion in Oncology</i> , 2022, 34, 362-370.	1.1	5
20	Functional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	6
21	SMARCA4-Deficient Thoracic Sarcoma. <i>International Journal of Surgical Pathology</i> , 2021, 29, 640-641.	0.4	3
22	<i>EWSR1-SMAD3</i> -Positive Fibroblastic Tumor. <i>International Journal of Surgical Pathology</i> , 2021, 29, 179-181.	0.4	7
23	Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 132-141.	1.9	9
24	Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. <i>Oncologist</i> , 2021, 26, e622-e631.	1.9	20
25	Sirolimus for patients with progressive epithelioid hemangioendothelioma. <i>Cancer</i> , 2021, 127, 504-506.	2.0	3
26	Gynecological Sarcomas: Molecular Characteristics, Behavior, and Histology-Driven Therapy. <i>International Journal of Surgical Pathology</i> , 2021, 29, 4-20.	0.4	6
27	Current Reality of Treating Advanced Soft Tissue Sarcoma as Illustrated by Case Studies. <i>Oncology</i> , 2021, 99, 8-16.	0.9	0
28	The role of [⁶⁸ Ga]Ga-DOTATATE PET/CT in wild-type KIT/PDGFR α gastrointestinal stromal tumours (GIST). <i>EJNMMI Research</i> , 2021, 11, 5.	1.1	4
29	Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients—A Position Paper from the National Leiomyosarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). <i>Cancers</i> , 2021, 13, 886.	1.7	17
30	Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. <i>Oncologist</i> , 2021, 26, e639-e649.	1.9	29
31	Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. <i>Clinical Cancer Research</i> , 2021, 27, 3861-3866.	3.2	22
32	Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas. <i>Npj Precision Oncology</i> , 2021, 5, 17.	2.3	23
33	Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. <i>Cancer Medicine</i> , 2021, 10, 2645-2659.	1.3	23
34	Avapritinib in unresectable or metastatic PDGFR α D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. <i>European Journal of Cancer</i> , 2021, 145, 132-142.	1.3	75
35	Extraskeletal osteosarcomas: current update. <i>Future Oncology</i> , 2021, 17, 825-835.	1.1	8
36	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	2.0	96

#	ARTICLE	IF	CITATIONS
37	Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 7873-7888.	0.7	105
38	Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11536-11536.	0.8	0
39	IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy. , 2021, 9, e002232.		10
40	Phase (Ph) 1b/2 evaluation of olaratumab in combination with gemcitabine and docetaxel in advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2021, 39, 11517-11517.	0.8	2
41	Next-generation sequencing for the management of sarcomas with no known driver mutations. <i>Current Opinion in Oncology</i> , 2021, 33, 315-322.	1.1	13
42	Managing the risk of toxicity in the treatment of elderly patients with soft tissue sarcomas. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 903-913.	1.0	1
43	Clinical management and outcomes of primary ovarian leiomyosarcoma “ Experience from a sarcoma specialist unit. <i>Gynecologic Oncology Reports</i> , 2021, 36, 100737.	0.3	9
44	Results of the phase 1b soft-tissue sarcoma (STS) portion of the global randomized, double-blind, placebo-controlled study of tazemetostat (TAZ) plus doxorubicin (DOX) as frontline therapy for advanced epithelioid sarcoma (ES).. <i>Journal of Clinical Oncology</i> , 2021, 39, 11563-11563.	0.8	2
45	Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. <i>Cancer Medicine</i> , 2021, 10, 3565-3574.	1.3	6
46	Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry. <i>Journal of Proteomics</i> , 2021, 241, 104236.	1.2	12
47	Articulatory Correlates of Stress Pattern Disturbances in Talkers With Dysarthria. <i>Journal of Speech, Language, and Hearing Research</i> , 2021, 64, 2287-2300.	0.7	4
48	The Evaluation of Health-Related Quality of Life Issues Experienced by Patients with Desmoid-Type Fibromatosis (The QUALIFIED Study)“A Protocol for an International Cohort Study. <i>Cancers</i> , 2021, 13, 3068.	1.7	9
49	Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas. <i>Cells</i> , 2021, 10, 1533.	1.8	14
50	What Matters to Us: Impact of Telemedicine During the Pandemic in the Care of Patients With Sarcoma Across Scotland. <i>JCO Global Oncology</i> , 2021, 7, 1067-1073.	0.8	9
51	The evolving management of epithelioid sarcoma. <i>European Journal of Cancer Care</i> , 2021, 30, e13489.	0.7	5
52	Abstract CT123: Population pharmacokinetics of ripretinib in patients with advanced malignancies. <i>Cancer Research</i> , 2021, 81, CT123-CT123.	0.4	1
53	Pharmacotherapy for liposarcoma: current and emerging synthetic treatments. <i>Future Oncology</i> , 2021, 17, 2659-2670.	1.1	6
54	CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes. , 2021, 9, e002812.		21

#	ARTICLE	IF	CITATIONS
55	Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2173-2181.	0.5	2
56	Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the <scp>INVICTUS</scp> Study. <i>Oncologist</i> , 2021, 26, e2053-e2060.	1.9	19
57	Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. <i>Future Oncology</i> , 2021, 17, 2923-2939.	1.1	10
58	Ripretinib inpatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2021, 155, 236-244.	1.3	19
59	Desmoid fibromatosis: is the current picture changing?. <i>Future Oncology</i> , 2021, 17, 3397-3408.	1.1	5
60	Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFRA</i> Mutations in the Phase III INVICTUS Study. <i>Clinical Cancer Research</i> , 2021, 27, 6333-6342.	3.2	25
61	Solitary fibrous tumor: molecular hallmarks and treatment for a rare sarcoma. <i>Future Oncology</i> , 2021, 17, 3627-3636.	1.1	15
62	Gastrointestinal leiomyosarcoma demonstrate a predilection for distant recurrence and poor response to systemic treatments. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2595-2601.	0.5	3
63	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3128-3139.	0.8	56
64	Future Directions in the Treatment of Osteosarcoma. <i>Cells</i> , 2021, 10, 172.	1.8	102
65	Olaratumab-induced Biomarker Modulation in Sarcomasâ€”Response. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2094-2094.	1.9	0
66	The perplexing role of immuno-oncology drugs in osteosarcoma. <i>Journal of Bone Oncology</i> , 2021, 31, 100400.	1.0	4
67	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1321-1337.	5.7	66
68	Dedifferentiated chondrosarcoma: current standards of care. <i>Future Oncology</i> , 2021, 17, 4983-4991.	1.1	2
69	The Extracellular Matrix in Soft Tissue Sarcomas: Pathobiology and Cellular Signalling. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 763640.	1.8	7
70	Imaging features of primary sites and metastatic patterns of angiosarcoma. <i>Insights Into Imaging</i> , 2021, 12, 189.	1.6	3
71	Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. <i>European Urology Focus</i> , 2020, 6, 999-1005.	1.6	5
72	Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARCO21) trial. <i>Journal of Geriatric Oncology</i> , 2020, 11, 463-469.	0.5	7

#	ARTICLE	IF	CITATIONS
73	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. <i>Cancer</i> , 2020, 126, 98-104.	2.0	25
74	Embryonal and Alveolar Rhabdomyosarcoma in Adults: Real-Life Data From a Tertiary Sarcoma Centre. <i>Clinical Oncology</i> , 2020, 32, e27-e35.	0.6	12
75	Proteomic research in sarcomas – current status and future opportunities. <i>Seminars in Cancer Biology</i> , 2020, 61, 56-70.	4.3	50
76	Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre. <i>Clinical Sarcoma Research</i> , 2020, 10, 1.	2.3	23
77	Adult soft tissue myoepithelial carcinoma: treatment outcomes and efficacy of chemotherapy. <i>Medical Oncology</i> , 2020, 37, 13.	1.2	18
78	Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. <i>ESMO Open</i> , 2020, 5, e000787.	2.0	22
79	Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. <i>Annals of Oncology</i> , 2020, 31, 1506-1517.	0.6	103
80	Diagnostic Differences in Expert Second-Opinion Consultation Cases at a Tertiary Sarcoma Center. <i>Sarcoma</i> , 2020, 2020, 1-11.	0.7	15
81	A Timely Oral Option: Single-Agent Vinorelbine in Desmoid Tumors. <i>Oncologist</i> , 2020, 25, e2013-e2016.	1.9	13
82	Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. <i>Lancet Oncology</i> , The, 2020, 21, 1423-1432.	5.1	194
83	Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers. <i>JCO Global Oncology</i> , 2020, 6, 1046-1051.	0.8	89
84	Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer. <i>European Journal of Cancer</i> , 2020, 136, 99-106.	1.3	31
85	Optimal Clinical Management and the Molecular Biology of Angiosarcomas. <i>Cancers</i> , 2020, 12, 3321.	1.7	15
86	Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma. <i>JAMA Oncology</i> , 2020, 6, 1778.	3.4	66
87	Epithelioid malignant peripheral nerve sheath tumor arising in schwannoma. <i>Rare Tumors</i> , 2020, 12, 203636132095086.	0.3	6
88	Paraneoplastic dermatomyositis associated with metastatic leiomyosarcoma of unknown primary. <i>Clinical Sarcoma Research</i> , 2020, 10, 15.	2.3	2
89	Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. <i>Journal of Clinical Oncology</i> , 2020, 38, 3294-3303.	0.8	61
90	Health-Related Quality of Life and Experiences of Sarcoma Patients during the COVID-19 Pandemic. <i>Cancers</i> , 2020, 12, 2288.	1.7	49

#	ARTICLE	IF	CITATIONS
91	Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue. <i>Anticancer Research</i> , 2020, 40, 7003-7007.	0.5	3
92	1621MO Long-term efficacy, tolerability and overall survival in patients (pts) with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumour (GIST) treated with avapritinib: NAVIGATOR phase I trial update. <i>Annals of Oncology</i> , 2020, 31, S973.	0.6	2
93	1622MO Clinical benefit with ripretinib as a 4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study. <i>Annals of Oncology</i> , 2020, 31, S973-S974.	0.6	1
94	1623MO Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I study. <i>Annals of Oncology</i> , 2020, 31, S974-S975.	0.6	3
95	1626MO Treatment expectations and preferences for quality versus quantity of life in patients with advanced soft tissue sarcomas starting palliative 1st line chemotherapy. <i>Annals of Oncology</i> , 2020, 31, S976.	0.6	0
96	1639P Integrated safety analysis of tazemetostat (TAZ) 800 mg BID in adult patients (pts) with hematologic and solid tumors. <i>Annals of Oncology</i> , 2020, 31, S981-S982.	0.6	0
97	A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. <i>Onc Immunology</i> , 2020, 9, 1847846.	2.1	22
98	Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland. <i>Clinical Sarcoma Research</i> , 2020, 10, 9.	2.3	5
99	Metastatic Soft Tissue Sarcomas in Adolescents and Young Adults: A Specialist Center Experience. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020, 9, 628-638.	0.7	10
100	Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. <i>Sarcoma</i> , 2020, 2020, 1-6.	0.7	17
101	Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates. <i>Current Treatment Options in Oncology</i> , 2020, 21, 55.	1.3	35
102	Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 923-934.	5.1	224
103	Robotic surgery for gastric gastrointestinal stromal tumors: A single center case series. <i>Journal of Surgical Oncology</i> , 2020, 122, 691-698.	0.8	7
104	Tropomyosin receptor kinase inhibitors in the management of sarcomas. <i>Current Opinion in Oncology</i> , 2020, 32, 307-313.	1.1	9
105	Health-related quality Of Life in patients with advanced Soft Tissue sarcomas treated with Chemotherapy (The HOLISTIC study): protocol for an international observational cohort study. <i>BMJ Open</i> , 2020, 10, e035171.	0.8	8
106	Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. <i>ESMO Open</i> , 2020, 5, e000604.	2.0	11
107	Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study. <i>British Journal of Cancer</i> , 2020, 122, 1158-1165.	2.9	17
108	Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. <i>Lancet Oncology</i> , The, 2020, 21, 935-946.	5.1	186

#	ARTICLE	IF	CITATIONS
109	O-13 Efficacy and safety of ripretinib as 4th-line therapy for patients with gastrointestinal stromal tumor following crossover from placebo: Analyses from INVICTUS. <i>Annals of Oncology</i> , 2020, 31, 236.	0.6	3
110	Superficial CD34-Positive Fibroblastic Tumor. <i>International Journal of Surgical Pathology</i> , 2020, 28, 879-881.	0.4	7
111	Rib destruction by epithelioid tumour in a young man. <i>Journal of Clinical Pathology</i> , 2020, 73, e2-e2.	1.0	1
112	Low-grade Fibromyxoid Sarcoma: Treatment Outcomes and Efficacy of Chemotherapy. <i>In Vivo</i> , 2020, 34, 239-245.	0.6	28
113	Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?. <i>Current Molecular Biology Reports</i> , 2020, 6, 1-9.	0.8	20
114	Durable tumor regression in highly refractory metastatic <i>KIT/PDGFR</i> wild-type GIST following treatment with nivolumab. <i>Oncolimmunology</i> , 2020, 9, 1710064.	2.1	8
115	Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 15-28.	1.1	6
116	Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1266.	3.8	190
117	Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy. , 2020, 8, e000247.		7
118	The sacral chordoma margin. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1415-1422.	0.5	29
119	Perineal mass in a 50-year-old man. <i>Journal of Clinical Pathology</i> , 2020, 73, e5-e5.	1.0	1
120	The Emerging Role of Platelets in the Formation of the Micrometastatic Niche: Current Evidence and Future Perspectives. <i>Frontiers in Oncology</i> , 2020, 10, 374.	1.3	23
121	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 96-107.	1.3	243
122	Primary ilioacaval leiomyosarcomas: The path beyond surgery. <i>European Journal of Surgical Oncology</i> , 2020, 46, 893-897.	0.5	8
123	A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1633-1637.	1.2	4
124	Quality of life (QoL) and self-reported function with ripretinib as 4th-line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11535-11535.	0.8	8
125	Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in 4th-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11539-11539.	0.8	3
126	Efficacy, safety, and immune priming effect of tazemetostat in patients with epithelioid sarcoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11564-11564.	0.8	1

#	ARTICLE	IF	CITATIONS
127	The route to diagnosis of sarcoma patients: Results from an interview study in the Netherlands and the United Kingdom. <i>PLoS ONE</i> , 2020, 15, e0243439.	1.1	8
128	Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors. <i>Future Oncology</i> , 2020, 16, 1641-1648.	1.1	7
129	The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma. <i>Scientific Reports</i> , 2019, 9, 14602.	1.6	22
130	Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. <i>Cancer</i> , 2019, 125, 4435-4441.	2.0	10
131	The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 971-991.	1.1	31
132	Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance. <i>Annals of Surgical Oncology</i> , 2019, 26, 4699-4706.	0.7	36
133	Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2019, 120, 132-139.	1.3	24
134	The Role of Local Therapy in Multi-focal Epithelioid Haemangioendothelioma. <i>Anticancer Research</i> , 2019, 39, 4891-4896.	0.5	13
135	Sarcomas and old age: few options for such a large patient population. <i>Future Oncology</i> , 2019, 15, 11-15.	1.1	8
136	Treatment of Desmoid Tumors in 2019. <i>JAMA Oncology</i> , 2019, 5, 567.	3.4	32
137	Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma. <i>BMC Cancer</i> , 2019, 19, 593.	1.1	13
138	Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). <i>Clinical Cancer Research</i> , 2019, 25, 5295-5300.	3.2	70
139	First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. <i>Clinical Cancer Research</i> , 2019, 25, 5808-5817.	3.2	66
140	Systemic Interferon- β Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial. <i>Cancer Immunology Research</i> , 2019, 7, 1237-1243.	1.6	82
141	Pazopanib in advanced soft tissue sarcomas. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 16.	7.1	57
142	Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 505-511.	1.9	13
143	A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb β 004) in metastatic soft-tissue sarcomas. <i>Cancer</i> , 2019, 125, 2445-2454.	2.0	19
144	Aldoxorubicin in soft tissue sarcomas. <i>Future Oncology</i> , 2019, 15, 1429-1435.	1.1	12

#	ARTICLE	IF	CITATIONS
145	Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients. <i>Anticancer Research</i> , 2019, 39, 347-351.	0.5	0
146	Negative phase III trials announce the need for biomarkers in sarcoma. <i>European Journal of Cancer</i> , 2019, 123, 81-82.	1.3	1
147	Imaging Soft-tissue Sarcomas of the Head and Neck: A Tertiary Soft-tissue Sarcoma Unit Experience. <i>Anticancer Research</i> , 2019, 39, 6223-6230.	0.5	3
148	Oncological Outcome After Diagnostic Biopsies in Gastrointestinal Stromal Tumors. <i>Annals of Surgery</i> , 2019, Publish Ahead of Print, e1093-e1098.	2.1	7
149	Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 191-199.	1.1	10
150	Optimising Cancer Vaccine Design in Sarcoma. <i>Cancers</i> , 2019, 11, 1.	1.7	211
151	Desmoid fibromatosis through the patients' eyes: time to change the focus and organisation of care?. <i>Supportive Care in Cancer</i> , 2019, 27, 965-980.	1.0	28
152	Ending 40 years of silence: Rationale for a new staging system for soft tissue sarcoma of the head and neck. <i>Clinical and Translational Radiation Oncology</i> , 2019, 15, 13-19.	0.9	7
153	Abstract C077: Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036)., 2019, , .		3
154	Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11003-11003.	0.8	50
155	ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA3-LBA3.	0.8	47
156	The SAINT: Initial results of a phase I/II study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 22-22.	0.8	2
157	Abstract CT058: Ripretinib (DCC-2618) pharmacokinetics (PK) in a Phase I study in patients with gastrointestinal stromal tumors (GIST) and other advanced malignancies: A retrospective evaluation of the PK effects of proton pump inhibitors (PPIs)., 2019, , .		0
158	Abstract CT009: A Phase Ib study assessing biomarker modulation in soft tissue sarcoma patients treated with olaratumab followed by olaratumab plus doxorubicin. , 2019, , .		0
159	Olaratumab in soft tissue sarcoma - Current status and future perspectives. <i>European Journal of Cancer</i> , 2018, 92, 33-39.	1.3	16
160	Endometrial Stromal Sarcoma With Hyalinizing Giant Rosettes, Mimicking Low-Grade Fibromyxoid Sarcoma. <i>International Journal of Surgical Pathology</i> , 2018, 26, 525-527.	0.4	2
161	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. <i>JAMA Oncology</i> , 2018, 4, e180219.	3.4	63
162	Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials. <i>Oncologist</i> , 2018, 23, 1250-1259.	1.9	25

#	ARTICLE	IF	CITATIONS
163	The current landscape of early drug development for patients with sarcoma in the immunotherapy era. <i>Future Oncology</i> , 2018, 14, 1197-1211.	1.1	11
164	Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. <i>Acta Oncologica</i> , 2018, 57, 958-964.	0.8	41
165	Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 147-151.	0.6	21
166	Safety and Efficacy Outcomes of Embolization in Hepatic Sarcomas. <i>American Journal of Roentgenology</i> , 2018, 210, 175-182.	1.0	21
167	Systemic therapy in retroperitoneal sarcoma management. <i>Journal of Surgical Oncology</i> , 2018, 117, 87-92.	0.8	13
168	Clinical and Molecular Spectrum of Liposarcoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 151-159.	0.8	183
169	Perspectives on the evolving state of the art management of gastrointestinal stromal tumours. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 21-21.	1.5	3
170	Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review. <i>Cancers</i> , 2018, 10, 417.	1.7	36
171	Bone sarcomas: ESMOâ€œPaedCanâ€œEURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv79-iv95.	0.6	380
172	Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. <i>Medical Oncology</i> , 2018, 35, 138.	1.2	26
173	Age-related sarcoma patient experience: results from a national survey in England. <i>BMC Cancer</i> , 2018, 18, 991.	1.1	28
174	Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response. <i>Clinical Sarcoma Research</i> , 2018, 8, 13.	2.3	32
175	Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1241-1248.	1.1	3
176	Trends in Modern Phase 1 Oncology Trials. <i>New England Journal of Medicine</i> , 2018, 379, 1188-1189.	13.9	3
177	Synovial Sarcoma of the Thyroid Gland, Diagnostic Pitfalls and Clinical Management. <i>Anticancer Research</i> , 2018, 38, 5275-5282.	0.5	6
178	Advances in the treatment of soft tissue sarcoma: focus on eribulin. <i>Cancer Management and Research</i> , 2018, Volume 10, 207-216.	0.9	9
179	Gastrointestinal stromal tumours: ESMOâ€œEURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv68-iv78.	0.6	413
180	Soft tissue and visceral sarcomas: ESMOâ€œEURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv51-iv67.	0.6	641

#	ARTICLE	IF	CITATIONS
181	Quality of life and patients'™ expectations in soft tissue sarcoma. <i>Future Oncology</i> , 2018, 14, 51-62.	1.1	12
182	Acral myxoinflammatory fibroblastic sarcoma with hybrid features of hemosiderotic fibrolipomatous tumor occurring 10%years after renal transplantation. <i>Rare Tumors</i> , 2018, 10, 203636131878262.	0.3	4
183	Pancreaticoduodenectomy for the Management of Pancreatic or Duodenal Metastases from Primary Sarcoma. <i>Anticancer Research</i> , 2018, 38, 4041-4046.	0.5	4
184	2018 ESMO Sarcoma and GIST Symposium: "take-home messages"™ in soft tissue sarcoma. <i>ESMO Open</i> , 2018, 3, e000390.	2.0	6
185	Risk"benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. <i>Future Oncology</i> , 2018, 14, 2663-2676.	1.1	105
186	Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. <i>Annals of Oncology</i> , 2018, 29, 1995-2002.	0.6	30
187	Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. <i>Medical Oncology</i> , 2018, 35, 131.	1.2	14
188	The Value of Neoadjuvant Chemotherapy in Localized High-Risk Soft-Tissue Sarcoma of the Extremities and Trunk. <i>JAMA Oncology</i> , 2018, 4, 1167.	3.4	10
189	Abstract 616: Interferon gamma induced transformation of the cold tumor microenvironment in patients with NY-ESO-1 expressing sarcomas. , 2018, , .		1
190	Effect of intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist G100 on a clinical response and CD4 T-cell response locally and systemically.. <i>Journal of Clinical Oncology</i> , 2018, 36, 71-71.	0.8	4
191	Clear Cell Sarcoma-like Tumor of the Gastrointestinal Tract: Clinical Outcome and Pathologic Features of a Molecularly Characterized Tertiary Center Case Series. <i>Anticancer Research</i> , 2018, 38, 1479-1483.	0.5	16
192	Gemcitabine re-challenge in metastatic soft tissue sarcoma: A therapeutic option for selected patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11559-11559.	0.8	0
193	TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS11590-TPS11590.	0.8	1
194	Lack of cardiac toxicity in patients treated with aldoxrubicin with doxorubicin equivalent doses beyond 1000mg/m2.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11585-11585.	0.8	1
195	Paediatric, adolescent, wild type, syndromic gastrointestinal stromal tumours (PAWS-GIST): Report from United Kingdom PAWS-GIST clinic.. <i>Journal of Clinical Oncology</i> , 2018, 36, e23519-e23519.	0.8	0
196	Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).. <i>Journal of Clinical Oncology</i> , 2018, 36, e23570-e23570.	0.8	0
197	The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities. <i>British Journal of Cancer</i> , 2017, 116, 669-678.	2.9	48
198	Novel therapeutic approaches in chondrosarcoma. <i>Future Oncology</i> , 2017, 13, 637-648.	1.1	96

#	ARTICLE	IF	CITATIONS
199	Phase III Soft Tissue Sarcoma Trials: Success or Failure?. Current Treatment Options in Oncology, 2017, 18, 19.	1.3	19
200	Tâ€cell infiltration and clonality correlate with programmed cell death protein 1 and programmed deathâ€ligand 1 expression in patients with soft tissue sarcomas. Cancer, 2017, 123, 3291-3304.	2.0	202
201	Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2017, 164, 395-400.	1.1	12
202	Eribulin in advanced liposarcoma and leiomyosarcoma. Expert Review of Anticancer Therapy, 2017, 17, 717-723.	1.1	13
203	Treatment of retroperitoneal sarcoma: current standards and new developments. Current Opinion in Oncology, 2017, 29, 260-267.	1.1	56
204	Pazopanib, a promising option for the treatment of aggressive fibromatosis. Anti-Cancer Drugs, 2017, 28, 421-426.	0.7	36
205	The Adequacy of Core Biopsy in the Assessment of Smooth Muscle Neoplasms of Soft Tissues. American Journal of Surgical Pathology, 2017, 41, 923-931.	2.1	35
206	Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. Annals of Oncology, 2017, 28, 1230-1242.	0.6	168
207	Qâ€TWIST: What really matters to the cancer patient?. Cancer, 2017, 123, 2200-2202.	2.0	12
208	Advances in the Pathology and Molecular Biology of Sarcomas and the Impact on Treatment. Clinical Oncology, 2017, 29, 471-480.	0.6	6
209	Treatment of soft tissue sarcoma: a focus on earlier stages. Future Oncology, 2017, 13, 13-21.	1.1	26
210	Olaratumab for the treatment of soft-tissue sarcoma. Future Oncology, 2017, 13, 2151-2157.	1.1	2
211	Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma. Medical Oncology, 2017, 34, 167.	1.2	35
212	Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study. European Journal of Cancer, 2017, 85, 114-121.	1.3	12
213	First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. Journal of Immunotherapy, 2017, 40, 302-306.	1.2	51
214	Desmoplastic small round cell tumor: evaluation of reverse transcription-polymerase chain reaction and fluorescence in situ hybridization as ancillary molecular diagnostic techniques. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 631-640.	1.4	28
215	Does histotype-tailored neoadjuvant therapy improve outcomes?. Nature Reviews Clinical Oncology, 2017, 14, 589-590.	12.5	1
216	Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARCO21): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncology, The, 2017, 18, 1089-1103.	5.1	214

#	ARTICLE	IF	CITATIONS
217	Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. <i>Gynecologic Oncology</i> , 2017, 146, 531-537.	0.6	51
218	An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PATients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). <i>Annals of Oncology</i> , 2017, 28, 2399-2408.	0.6	274
219	Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. <i>Acta Oncol</i> 36, 2017, 56, 88-92.	0.8	146
220	Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. <i>Future Oncology</i> , 2017, 13, 93-107.	1.1	99
221	Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors. <i>Future Oncology</i> , 2017, 13, 185-194.	1.1	8
222	The Current Landscape of Early Drug Development for Patients With Sarcoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 807-810.	1.8	3
223	A molecular signature predictive of clinical outcome following pazopanib therapy in advanced soft tissue sarcoma. <i>Annals of Oncology</i> , 2017, 28, x149.	0.6	2
224	Systemic Therapy in Metastatic or Unresectable Well-Differentiated/Dedifferentiated Liposarcoma. <i>Frontiers in Oncology</i> , 2017, 7, 292.	1.3	31
225	SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. <i>Sarcoma</i> , 2017, 2017, 1-8.	0.7	55
226	Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series. <i>Clinical Sarcoma Research</i> , 2017, 7, 15.	2.3	38
227	Myoepithelial Carcinoma of the Paracecal Mesentery: Aggressive Behavior of a Rare Neoplasm at an Unusual Anatomic Site. <i>Rare Tumors</i> , 2017, 9, 38-41.	0.3	3
228	Olaratumab: a platelet-derived growth factor receptor- α -blocking antibody for the treatment of soft tissue sarcoma. <i>Clinical Pharmacology: Advances and Applications</i> , 2017, Volume 9, 159-164.	0.8	4
229	Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. <i>Journal of Clinical Oncology</i> , 2017, 35, 3433-3439.	0.8	126
230	Title is missing!. , 2017, , .		5
231	Neoadjuvant chemotherapy in localised soft-tissue sarcomas: where do we go from here?. <i>Lancet Oncology</i> , The, 2017, 18, 706-707.	5.1	6
232	Abstract 2947: Intratumoral injection of the toll-like receptor 4 agonist G100 induces a T-cell response in the soft tissue sarcoma microenvironment. , 2017, , .		6
233	Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11011-11011.	0.8	16
234	Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11058-11058.	0.8	21

#	ARTICLE	IF	CITATIONS
235	Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: Results of a retrospective multi-institutional case series.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11065-11065.	0.8	2
236	A randomized, double-blind, placebo-controlled, phase III study of crenolanib in advanced or metastatic GIST patients bearing a D842V mutation in <i>PDGFRA</i> : The CrenoGIST study.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS11080-TPS11080.	0.8	11
237	Tappas: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS11081-TPS11081.	0.8	5
238	Olaratumab for the treatment of soft tissue sarcoma. <i>Drugs of Today</i> , 2017, 53, 247.	0.7	6
239	Correlation of T-cell infiltration and clonality with PD-L1 expression in soft tissue sarcomas.. <i>Journal of Clinical Oncology</i> , 2017, 35, 23-23.	0.8	0
240	Does <i>MGMT</i> (O6-methylguanine- α -DNA methyltransferase) have a role in metastatic Ewing sarcoma (ES) patients (pts) undergoing temozolomide (TMZ) and irinotecan (IRI)?. <i>Journal of Clinical Oncology</i> , 2017, 35, 11030-11030.	0.8	0
241	Safety and efficacy of trabectedin when administered in the inpatient vs. outpatient setting in a subset analysis of a phase III randomized clinical trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, e22516-e22516.	0.8	0
242	The Imaging and Pathological Features of Metastatic Leiomyosarcoma in the Gallbladder. <i>Rare Tumors</i> , 2016, 8, 179-181.	0.3	2
243	Soft Tissue Myoepithelial Carcinoma Metastatic to the Cecum: Highlighting an Unusual Metastatic Pattern and the Need for Diagnostic Awareness. <i>Rare Tumors</i> , 2016, 8, 20-23.	0.3	4
244	Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin. <i>Cancer Management and Research</i> , 2016, Volume 8, 95-104.	0.9	12
245	A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas. <i>Sarcoma</i> , 2016, 2016, 1-9.	0.7	27
246	Targeting gastrointestinal stromal tumors: the role of regorafenib. <i>OncoTargets and Therapy</i> , 2016, 9, 3009.	1.0	5
247	Patient perspective of the diagnostic sarcoma pathway; results from a national sarcoma patient survey in England. <i>Annals of Oncology</i> , 2016, 27, vi488.	0.6	0
248	Dedifferentiated Liposarcoma. <i>Advances in Anatomic Pathology</i> , 2016, 23, 30-40.	2.4	97
249	Epithelioid Sarcoma. <i>Advances in Anatomic Pathology</i> , 2016, 23, 41-49.	2.4	95
250	Cardiac safety and toxicity minimization of regorafenib treatment. <i>Colorectal Cancer</i> , 2016, 5, 1-3.	0.8	1
251	Dear John Hunter. <i>BMJ</i> , 2016, 355, i6515.	3.0	2
252	Preliminary safety and activity in a first-in-human phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT and PDGFR β activation loop mutants in advanced gastrointestinal stromal tumor (GIST). <i>European Journal of Cancer</i> , 2016, 69, S4.	1.3	0

#	ARTICLE	IF	CITATIONS
253	Drug repositioning in sarcomas and other rare tumors. <i>EBioMedicine</i> , 2016, 6, 4-5.	2.7	4
254	Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells. <i>British Journal of Cancer</i> , 2016, 115, 473-479.	2.9	23
255	Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies. <i>Annals of Diagnostic Pathology</i> , 2016, 25, 64-71.	0.6	124
256	Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. <i>Clinical Sarcoma Research</i> , 2016, 6, 15.	2.3	80
257	Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group. <i>Annals of Surgical Oncology</i> , 2016, 23, 3531-3540.	0.7	136
258	Desmoplastic Small Round Cell Tumor. <i>International Journal of Surgical Pathology</i> , 2016, 24, 672-684.	0.4	50
259	PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3898-3905.	0.8	151
260	Rare Aggressive Behavior of <i>MDM2</i> -Amplified Retroperitoneal Dedifferentiated Liposarcoma, with Brain, Lung and Subcutaneous Metastases. <i>Rare Tumors</i> , 2016, 8, 105-108.	0.3	5
261	Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. <i>Annals of Oncology</i> , 2016, 27, vi488.	0.6	0
262	Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. <i>Lancet</i> , The, 2016, 388, 488-497.	6.3	512
263	Treatment of resectable intrathoracic sarcomas: a single institution experience over twenty years. <i>Journal of Radiation Oncology</i> , 2016, 5, 169-177.	0.7	3
264	The Current Status of Solitary Fibrous Tumor. <i>International Journal of Surgical Pathology</i> , 2016, 24, 281-292.	0.4	150
265	p.(L576P) <i>KIT</i> mutation in GIST: Favorable prognosis and sensitive to imatinib?. <i>Cancer Biology and Therapy</i> , 2016, 17, 543-545.	1.5	6
266	Phosphoproteomics in translational research: a sarcoma perspective. <i>Annals of Oncology</i> , 2016, 27, 787-794.	0.6	34
267	Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 501-512.	1.3	4
268	Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancerâ€“Soft Tissue and Bone Sarcoma Group (EORTCâ€“STBSG) recommendations for pathological examination and reporting. <i>European Journal of Cancer</i> , 2016, 53, 84-95.	1.3	99
269	The state of Illinois obstetric hemorrhage project: pre-project and post-training examination scores. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2016, 29, 845-849.	0.7	9
270	Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 786-793.	0.8	647

#	ARTICLE	IF	CITATIONS
271	Histology-Driven Therapy. <i>International Journal of Surgical Pathology</i> , 2016, 24, 5-15.	0.4	34
272	Patient-reported outcomes from randomized, phase-3 study of trabectedin (T) vs. dacarbazine (D) in advanced leiomyosarcoma (LMS) or liposarcoma (LPS).. <i>Journal of Clinical Oncology</i> , 2016, 34, 11061-11061.	0.8	5
273	Single-agent LV305 to induce anti-tumor immune and clinical responses in patients with advanced or metastatic sarcoma and other cancers expressing NY-ESO-1.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3093-3093.	0.8	3
274	Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2016, 37, 125-130.	0.1	3
275	Using G100 (Glucopyranosyl Lipid A) to transform the sarcoma tumor immune microenvironment.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11017-11017.	0.8	0
276	Temozolamide and irinotecan in metastatic Ewing sarcoma: An Italian Sarcoma Group and Royal Marsden Hospital join study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11033-11033.	0.8	0
277	3444 Low dose oral cyclophosphamide (LDOC) with prednisolone in the treatment of advanced adult soft tissue sarcoma (STS). <i>European Journal of Cancer</i> , 2015, 51, S703.	1.3	0
278	Clinical trial design methodologies for advanced sarcoma therapy. <i>Clinical Research and Regulatory Affairs</i> , 2015, 32, 70-73.	2.1	0
279	1321 Efficacy and safety of trabectedin (T) or dacarbazine (D) in an elderly patient subgroup (65 years) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior chemotherapy. <i>European Journal of Cancer</i> , 2015, 51, S194.	1.3	0
280	2026 A Phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. <i>European Journal of Cancer</i> , 2015, 51, S336-S337.	1.3	0
281	The effect of surgery with radiation on pelvic Ewing sarcoma survival. <i>Journal of Surgical Oncology</i> , 2015, 112, 861-865.	0.8	17
282	Synovial sarcoma diagnosis and management in the era of targeted therapies. <i>Current Opinion in Oncology</i> , 2015, 27, 316-322.	1.1	25
283	Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma. <i>Rare Tumors</i> , 2015, 7, 86-88.	0.3	30
284	Trabectedin in Soft Tissue Sarcomas. <i>Marine Drugs</i> , 2015, 13, 974-983.	2.2	16
285	Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy. <i>Frontiers in Oncology</i> , 2015, 5, 186.	1.3	34
286	Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2015, 26, 75-80.	0.6	95
287	Cardio-oncology: a special focus issue from <i>Future Oncology</i> . <i>Future Oncology</i> , 2015, 11, 1993-1994.	1.1	0
288	Cardio-oncology: an ongoing evolution. <i>Future Oncology</i> , 2015, 11, 2059-2066.	1.1	12

#	ARTICLE	IF	CITATIONS
289	Redefining the standard of care in metastatic leiomyosarcoma. <i>Lancet Oncology</i> , The, 2015, 16, 360-362.	5.1	5
290	Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 693-700.	3.2	81
291	A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma. <i>Clinical Sarcoma Research</i> , 2015, 5, 13.	2.3	44
292	Treatment of Chest Wall Sarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 80-86.	0.6	16
293	Quality of life measures in soft tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 95-100.	1.1	18
294	Current and advancing systemic treatment options for soft tissue sarcomas. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2023-2037.	0.9	1
295	A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 777-784.	1.1	17
296	A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFR α) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2015, 33, 10501-10501.	0.8	15
297	A phase I/II clinical trial of belinostat (PXD101) in combination with doxorubicin in patients with soft tissue sarcomas (STS).. <i>Journal of Clinical Oncology</i> , 2015, 33, 10516-10516.	0.8	3
298	Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3021-3021.	0.8	8
299	Dermatofibrosarcoma protuberans: from translocation to targeted therapy. <i>Cancer Biology and Medicine</i> , 2015, 12, 375-84.	1.4	39
300	PM00104 (Zalypsis [®]): A Marine Derived Alkylating Agent. <i>Molecules</i> , 2014, 19, 12328-12335.	1.7	28
301	Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8+ T cells. , 2014, 2, 36.		57
302	Success Is Not Final and Failure Is Not Fatal. <i>Journal of Clinical Oncology</i> , 2014, 32, 3449-3450.	0.8	0
303	Analysis of Clinical Prognostic Factors for Adult Patients with Head and Neck Sarcomas. <i>Otolaryngology - Head and Neck Surgery</i> , 2014, 151, 976-983.	1.1	22
304	The multidisciplinary management of giant cell tumor of bone. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 783-790.	1.1	13
305	Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity. <i>Cell Reports</i> , 2014, 6, 514-527.	2.9	239
306	Systemic therapy in advanced uterine adenosarcoma with sarcomatous overgrowth. <i>Gynecologic Oncology</i> , 2014, 132, 513.	0.6	4

#	ARTICLE	IF	CITATIONS
307	A Phase II multicenter, open-label, clinical and pharmacokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors. <i>Investigational New Drugs</i> , 2014, 32, 171-177.	1.2	11
308	Myxoid Liposarcomas Demonstrate a Profound Response to Neoadjuvant Radiation Therapy: An MRI-Based Volumetric Analysis and Pathological Correlation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, S756-S757.	0.4	4
309	A Contemporary Large Single-Institution Evaluation of Resected Retroperitoneal Sarcoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 2150-2158.	0.7	65
310	Management and outcome of metastatic clear cell sarcoma. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1383.	0.5	2
311	Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics. <i>Human Pathology</i> , 2014, 45, 1563-1571.	1.1	42
312	Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10520-10520.	0.8	14
313	Gemcitabine (G) and docetaxel (D) in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10541-10541.	0.8	1
314	Delayed development of a rhabdomyosarcoma following radiation for a spinal cord glioma. <i>Journal of Neuro-Oncology</i> , 2013, 112, 115-118.	1.4	5
315	Clinical benefit of trabectedin in uterine adenosarcoma. <i>Medical Oncology</i> , 2013, 30, 501.	1.2	20
316	The Use of Radiofrequency Ablation in Gastrointestinal Stromal Tumor. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 751.	0.2	0
317	The evolution of systemic therapy in sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 211-223.	1.1	23
318	Treatment of Resectable Intrathoracic Sarcomas: A Single Institution Experience Over 20 Years. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, S617.	0.4	0
319	An evaluation of [¹⁸ F]fluorodeoxyglucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing Sarcoma. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1113-1117.	0.8	74
320	KIT signaling regulates primordial follicle formation in the neonatal mouse ovary. <i>Developmental Biology</i> , 2013, 382, 186-197.	0.9	60
321	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2013, 381, 295-302.	6.3	1,144
322	Management of gastrointestinal stromal tumors. <i>Future Oncology</i> , 2013, 9, 193-206.	1.1	28
323	The efficacy of caffeine-potentiated chemotherapy in clear cell sarcoma. <i>International Journal of Clinical Oncology</i> , 2013, 18, 356-356.	1.0	0
324	New drugs and clinical trial design in advanced sarcoma: have we made any progress?. <i>Future Oncology</i> , 2013, 9, 1409-1411.	1.1	7

#	ARTICLE	IF	CITATIONS
325	Diagnosis, prognosis, and management of leiomyosarcoma. <i>Current Opinion in Oncology</i> , 2013, 25, 384-389.	1.1	41
326	Phase I Trial of Preoperative Chemoradiation plus Sorafenib for High-Risk Extremity Soft Tissue Sarcomas with Dynamic Contrast-Enhanced MRI Correlates. <i>Clinical Cancer Research</i> , 2013, 19, 6902-6911.	3.2	61
327	Multiple Liver Abscess Formation and Primary Gastrointestinal Stromal Tumor. <i>Rare Tumors</i> , 2013, 5, 167-168.	0.3	2
328	Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma. <i>Sarcoma</i> , 2013, 2013, 1-6.	0.7	54
329	Role of the Antiapoptotic Proteins BCL2 and MCL1 in the Neonatal Mouse Ovary1. <i>Biology of Reproduction</i> , 2013, 88, 46.	1.2	25
330	Bone Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 688-723.	2.3	106
331	Impact of 18F-FDG PET/CT Imaging in Therapeutic Decisions for Malignant Solitary Fibrous Tumor of the Pelvis. <i>Clinical Nuclear Medicine</i> , 2013, 38, 453-455.	0.7	11
332	Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib. <i>OncoTargets and Therapy</i> , 2013, 6, 217.	1.0	16
333	Abstract C47: Inference of tumor evolution during chemotherapy by computational modeling and single cell analysis of diversity.. , 2013, , .		0
334	Abstract P1-08-03: Prediction of response to neoadjuvant chemotherapy in estrogen receptor positive (ER+) breast cancer by IHC4 or Ki67 alone. , 2013, , .		0
335	Systemic therapy in primary angiosarcoma of the spleen. <i>Rare Tumors</i> , 2012, 4, 178-180.	0.3	19
336	Role of Palliative Chemotherapy in Advanced Epithelioid Sarcoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 351-357.	0.6	54
337	Reducing Maternal Deaths Through State Maternal Mortality Review. <i>Journal of Women's Health</i> , 2012, 21, 905-909.	1.5	33
338	Treatment of Chest Wall Sarcomas: A Single Institution Experience Over 20 Years. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, S658.	0.4	1
339	Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour. <i>Acta Oncologica</i> , 2012, 51, 550-554.	0.8	44
340	Molecular Classification of Breast Cancer. <i>Surgical Pathology Clinics</i> , 2012, 5, 701-717.	0.7	10
341	MDM2 inhibition in liposarcoma: a step in the right direction. <i>Lancet Oncology</i> , The, 2012, 13, 1070-1071.	5.1	15
342	NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. <i>Cancer</i> , 2012, 118, 4564-4570.	2.0	107

#	ARTICLE	IF	CITATIONS
343	Know Before They Go: A Time/Cost Analysis of an Early Screening and Referral Pilot Program for Postpartum Depression. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2012, 41, S23-S24.	0.2	0
344	NYESO-1/LAGE-1s and PRAME Are Targets for Antigen Specific T Cells in Chondrosarcoma following Treatment with 5-Aza-2-Deoxycytabine. <i>PLoS ONE</i> , 2012, 7, e32165.	1.1	52
345	Advanced aggressive fibromatosis: Effective palliation with chemotherapy. <i>Acta Oncol³gica</i> , 2011, 50, 455-461.	0.8	55
346	Leiomyosarcomas of the inferior vena cava: diagnostic features on cross-sectional imaging. <i>Clinical Radiology</i> , 2011, 66, 50-56.	0.5	48
347	Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. <i>European Journal of Cancer</i> , 2011, 47, 138-150.	1.3	124
348	Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study. <i>European Journal of Cancer</i> , 2011, 47, 1006-1012.	1.3	88
349	Immune-Based Therapies for Sarcoma. <i>Sarcoma</i> , 2011, 2011, 1-7.	0.7	29
350	Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers. <i>Gynecologic Oncology</i> , 2011, 123, 553-556.	0.6	68
351	Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 423-429.	1.1	14
352	Chemotherapy in clear cell sarcoma. <i>Medical Oncology</i> , 2011, 28, 859-863.	1.2	58
353	Nuclear NF- κ B/p65 expression and response to neoadjuvant chemotherapy in breast cancer. <i>Journal of Clinical Pathology</i> , 2011, 64, 130-135.	1.0	25
354	Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations. <i>Sarcoma</i> , 2011, 2011, 1-13.	0.7	54
355	Fungal spinal cord compression in metastatic synovial sarcoma. <i>Acta Oncol³gica</i> , 2011, 50, 158-159.	0.8	3
356	Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial.. <i>Journal of Clinical Oncology</i> , 2011, 29, 10000-10000.	0.8	13
357	Creatinine clearance and serum albumin as factors for encephalopathy with ambulatory 14-day infusional ifosfamide for advanced liposarcomas.. <i>Journal of Clinical Oncology</i> , 2011, 29, 10087-10087.	0.8	0
358	Biological Rationale and Current Clinical Experience With Anti-Insulin-Like Growth Factor 1 Receptor Monoclonal Antibodies in Treating Sarcoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 183-194.	1.0	63
359	Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 315-323.	1.1	98
360	Beyond triple-negative breast cancer: the need to define new subtypes. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1197-1213.	1.1	18

#	ARTICLE	IF	CITATIONS
361	Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma. <i>Sarcoma</i> , 2010, 2010, 1-8.	0.7	24
362	PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. <i>Modern Pathology</i> , 2010, 23, 1334-1345.	2.9	61
363	Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. <i>European Journal of Surgical Oncology</i> , 2010, 36, 477-482.	0.5	83
364	Atypical metastatic profile in Stewart-Treves syndrome. <i>Acta OncolÃ³gica</i> , 2010, 49, 1388-1390.	0.8	0
365	Systemic therapy in clear cell sarcoma.. <i>Journal of Clinical Oncology</i> , 2010, 28, 10098-10098.	0.8	1
366	Nuclear NF-kb/p65 expression and response to neoadjuvant chemotherapy in breast cancer.. <i>Journal of Clinical Oncology</i> , 2010, 28, 611-611.	0.8	2
367	A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. <i>British Journal of Cancer</i> , 2009, 100, 305-310.	2.9	36
368	A feasibility study of sequential doublet chemotherapy comprising carboplatinâ€“doxorubicin and carboplatinâ€“paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma. <i>Annals of Oncology</i> , 2009, 20, 1787-1793.	0.6	10
369	Genomic profile of a secretory breast cancer with an ETV6-NTRK3 duplication. <i>Journal of Clinical Pathology</i> , 2009, 62, 604-612.	1.0	46
370	The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 53-68.	1.1	244
371	Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. <i>European Journal of Cancer</i> , 2009, 45, 2930-2934.	1.3	113
372	Biomarkers and predictive factors of response to neoadjuvant treatment. <i>Breast Cancer Research</i> , 2009, 11, .	2.2	0
373	9421 The role of chemotherapy in aggressive fibromatosis. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 596.	2.2	0
374	Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 245-256.	1.1	62
375	Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 27-44.	1.1	287
376	Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1311-1317.	0.6	50
377	Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype. <i>Leukemia and Lymphoma</i> , 2008, 49, 2284-2290.	0.6	2
378	Paclitaxel in the management of ovarian cancer. <i>Expert Review of Obstetrics and Gynecology</i> , 2008, 3, 287-299.	0.4	0

#	ARTICLE	IF	CITATIONS
379	Methylated <i>NEUROD1</i> Promoter is a Marker for Chemosensitivity in Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 3494-3502.	3.2	37
380	Debulking Hepatectomy for an Unusual Case of a Grade 1 Stage 1 Granulosa Cell Tumour of the Ovary with Late Metastases. <i>Oncology</i> , 2007, 72, 143-144.	0.9	5
381	Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. <i>Lancet Oncology</i> , The, 2007, 8, 595-602.	5.1	416
382	Caveolin 1 Is Overexpressed and Amplified in a Subset of Basal-like and Metaplastic Breast Carcinomas: A Morphologic, Ultrastructural, Immunohistochemical, and In situ Hybridization Analysis. <i>Clinical Cancer Research</i> , 2007, 13, 90-101.	3.2	202
383	Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 181-189.	1.1	101
384	Anthracycline cardiotoxicity. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 791-809.	1.0	108
385	Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1249-1269.	1.1	75
386	Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. <i>Lancet Oncology</i> , The, 2006, 7, 869-874.	5.1	60
387	Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. <i>Modern Pathology</i> , 2006, 19, 307-319.	2.9	87
388	Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. <i>Modern Pathology</i> , 2006, 19, 999-1009.	2.9	143
389	MYC amplification in breast cancer: a chromogenic in situ hybridisation study. <i>Journal of Clinical Pathology</i> , 2006, 60, 1017-1023.	1.0	58
390	Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. <i>British Journal of Cancer</i> , 2006, 94, 358-362.	2.9	96
391	The development and application of imatinib. <i>Expert Opinion on Drug Safety</i> , 2005, 4, 183-191.	1.0	37
392	Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity. <i>Lancet Oncology</i> , The, 2005, 6, 67.	5.1	7
393	Differential sensitivity of liposarcoma subtypes to chemotherapy. <i>European Journal of Cancer</i> , 2005, 41, 2853-2860.	1.3	290
394	Tumour vaccine associated lymphadenopathy and false positive positron emission tomography scan changes. <i>British Journal of Radiology</i> , 2004, 77, 74-75.	1.0	35
395	Efficacy and safety of trastuzumab. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 317-327.	1.0	23
396	Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin. <i>Lancet Oncology</i> , The, 2004, 5, 575-577.	5.1	21

#	ARTICLE	IF	CITATIONS
397	Clinical and Molecular Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2003, 2, 235-238.	1.0	0
398	Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?. <i>British Journal of Cancer</i> , 2003, 89, 36-42.	2.9	68
399	Virtual Biopsy in Soft Tissue Sarcoma. How Close Are We?. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6